(0.06%) 5 183.92 points
(0.04%) 38 868 points
(-0.15%) 16 324 points
(0.03%) $78.50
(0.32%) $2.20
(-0.42%) $2 321.50
(-0.46%) $27.49
(2.30%) $987.05
(0.23%) $0.930
(0.89%) $10.92
(0.49%) $0.800
(-0.09%) $91.26
2 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 0.00%
-3.57% $ 12.15
Live Chart Being Loaded With Signals
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally...
Stats | |
---|---|
Volumen de hoy | 53 733.00 |
Volumen promedio | 110 519 |
Capitalización de mercado | 28.16B |
EPS | $0.598 ( 2023-06-30 ) |
Próxima fecha de ganancias | ( $0.0800 ) 2024-05-09 |
Last Dividend | $0.0740 ( 2023-05-19 ) |
Next Dividend | $0 ( N/A ) |
P/E | 37.97 |
ATR14 | $0.0520 (0.43%) |
Volumen Correlación
Coloplast A/S Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Coloplast A/S Correlación - Moneda/Commodity
Coloplast A/S Finanzas
Annual | 2023 |
Ingresos: | $24.50B |
Beneficio Bruto: | $16.33B (66.64 %) |
EPS: | $22.21 |
FY | 2023 |
Ingresos: | $24.50B |
Beneficio Bruto: | $16.33B (66.64 %) |
EPS: | $22.21 |
FY | 2022 |
Ingresos: | $22.58B |
Beneficio Bruto: | $15.53B (68.78 %) |
EPS: | $22.15 |
FY | 2021 |
Ingresos: | $19.43B |
Beneficio Bruto: | $13.31B (68.53 %) |
EPS: | $2.27 |
Financial Reports:
No articles found.
Coloplast A/S Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0.210 (N/A) |
$0 (N/A) |
$0.0740 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0810 | 2021-05-14 |
Last Dividend | $0.0740 | 2023-05-19 |
Next Dividend | $0 | N/A |
Payout Date | 2023-05-30 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | $0.649 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.9 | -- |
Div. Sustainability Score | 6.57 | |
Div.Growth Potential Score | 5.74 | |
Div. Directional Score | 6.15 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SRCU | Ex Dividend Knight | 2023-08-14 | Quarterly | 0 | 0.00% | |
HALMY | Ex Dividend Knight | 2023-07-14 | Semi-Annually | 0 | 0.00% | |
AGRIP | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
NNGRY | Ex Dividend Junior | 2023-09-07 | Annually | 0 | 0.00% | |
CODQL | Ex Dividend Knight | 2023-08-28 | Semi-Annually | 0 | 0.00% | |
TRBK | Ex Dividend Junior | 2023-08-03 | Semi-Annually | 0 | 0.00% | |
IBDRY | Ex Dividend Knight | 2023-07-07 | Semi-Annually | 0 | 0.00% | |
ASMVY | Ex Dividend Junior | 2023-08-18 | Semi-Annually | 0 | 0.00% | |
POAHY | Ex Dividend Knight | 2023-06-30 | Annually | 0 | 0.00% | |
DURYY | Ex Dividend Junior | 2023-05-15 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.195 | 1.500 | 6.11 | 9.16 | [0 - 0.5] |
returnOnAssetsTTM | 0.100 | 1.200 | 6.66 | 7.99 | [0 - 0.3] |
returnOnEquityTTM | 0.424 | 1.500 | 6.40 | 9.60 | [0.1 - 1] |
payoutRatioTTM | 0.957 | -1.000 | 0.433 | -0.433 | [0 - 1] |
currentRatioTTM | 0.532 | 0.800 | -2.34 | -1.871 | [1 - 3] |
quickRatioTTM | 0.324 | 0.800 | -2.80 | -2.24 | [0.8 - 2.5] |
cashRatioTTM | 0.0484 | 1.500 | -0.842 | -1.263 | [0.2 - 2] |
debtRatioTTM | 0.445 | -1.500 | 2.58 | -3.87 | [0 - 0.6] |
interestCoverageTTM | 9.31 | 1.000 | 7.66 | 7.66 | [3 - 30] |
operatingCashFlowPerShareTTM | 25.30 | 2.00 | 1.568 | 3.14 | [0 - 30] |
freeCashFlowPerShareTTM | 19.61 | 2.00 | 0.195 | 0.389 | [0 - 20] |
debtEquityRatioTTM | 1.430 | -1.500 | 4.28 | -6.42 | [0 - 2.5] |
grossProfitMarginTTM | 0.667 | 1.000 | 2.21 | 2.21 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.273 | 1.000 | 6.53 | 6.53 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.256 | 1.000 | 9.69 | 9.69 | [0.2 - 2] |
assetTurnoverTTM | 0.515 | 0.800 | 9.90 | 7.92 | [0.5 - 2] |
Total Score | 6.57 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 3.92 | 1.000 | 9.71 | 0 | [1 - 100] |
returnOnEquityTTM | 0.424 | 2.50 | 7.69 | 9.60 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 19.61 | 2.00 | 3.46 | 0.389 | [0 - 30] |
dividendYielPercentageTTM | 0.0509 | 1.500 | 8.73 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 25.30 | 2.00 | 1.568 | 3.14 | [0 - 30] |
payoutRatioTTM | 0.957 | 1.500 | 0.433 | -0.433 | [0 - 1] |
pegRatioTTM | 2.09 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.221 | 1.000 | 6.97 | 0 | [0.1 - 0.5] |
Total Score | 5.74 |
Coloplast A/S
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico